scholarly journals Nonsurgical Options for the Treatment of Basal Cell Carcinoma

2019 ◽  
pp. 75-81 ◽  
Author(s):  
John Paoli ◽  
Johan Dahlén Gyllencreutz ◽  
Julia Fougelberg ◽  
Eva Johansson Backman ◽  
Maja Modin ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Extensive Literature ◽  
Individualized Management ◽  
Therapeutic Alternatives ◽  
Treatment Alternatives ◽  
Histopathological Subtype

Objectives: The aim of this review article is to summarize the effectiveness, potential adverse events, and indications of the main nonsurgical treatment alternatives for basal cell carcinoma. Methods: An extensive literature review was carried out. The most relevant articles were discussed and selected by the authors in order to provide a brief but evidence-based overview of the most common nonsurgical methods used for treating basal cell carcinoma. Results: Although surgery and Mohs micrographic surgery are often considered the optimal treatment options for basal cell carcinoma, these tumors can also be treated successfully with destructive techniques (eg, curettage alone, cryosurgery, or electrodesiccation), photodynamic therapy, topical drugs (eg, 5-fluorouracil, imiquimod, or ingenol mebutate), radiotherapy, or hedgehog pathway inhibitors. When choosing between these alternatives, physicians must take into consideration the tumor’s size, location, and histopathological subtype. Special care should be taken when treating recurrent tumors. Furthermore, physician experience is of great importance when using destructive techniques. Finally, patient preference, potential adverse events, and cosmetic outcome should also be considered. Conclusions: Dermatologists and physicians treating basal cell carcinoma should have knowledge of and experience with the large arsenal of therapeutic alternatives available for the successful, safe, and individualized management of patients with basal cell carcinoma.

A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma

2021 ◽  
Author(s):  
Natalie Kash ◽  
Sirunya Silapunt
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Gold Standard ◽  
Treatment Options ◽  
Tumor Characteristics ◽  
Tumor Clearance ◽  
Superficial Basal Cell Carcinoma ◽  
Us Fda ◽  
Cure Rates

Although surgical therapy continues to be the gold standard for the treatment of basal cell carcinoma given high cure rates and the ability to histologically confirm tumor clearance, there are a number of nonsurgical treatment options that may be considered based on individual tumor characteristics, functional and cosmetic considerations, patient comorbidities and patient preference. Topical 5-fluorouracil 5% cream and imiquimod 5% cream have been US FDA-approved for the treatment of superficial basal cell carcinoma. Additionally, a number of new and emerging topical agents and techniques have been described for the treatment of basal cell carcinoma and will be reviewed herein.

scholarly journals Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

2016 ◽  
Vol 21 (10) ◽  
pp. 1218-1229 ◽  
Author(s):  
Mario E. Lacouture ◽  
Brigitte Dréno ◽  
Paolo Antonio Ascierto ◽  
Reinhard Dummer ◽  
Nicole Basset‐Seguin ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma

2017 ◽  
Vol 13 (2) ◽  
pp. 175-184 ◽  
Author(s):  
Kate Fife ◽  
Robert Herd ◽  
Susan Lalondrelle ◽  
Ruth Plummer ◽  
Amy Strong ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Basal Cell

Basal Cell Carcinoma: Epidemiology, Risk Factors, and Treatment Options

2017 ◽  
Author(s):  
Jeffrey M Farma ◽  
Elena P Lamb
Keyword(s):  
Risk Factors ◽  
Photodynamic Therapy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Sun Exposure ◽  
Hedgehog Pathway ◽  
Treatment Modalities ◽  
Genetic Syndromes

Ultraviolent (UV) solar radiation is considered to be the dominant risk factor for development of basal cell carcinoma (BCC). The development of BCC is thought to arise from intense, intermittent sun exposure leading to burns. Identifying patients with high-risk factors for developing BCC includes chronic immunosuppression, exposure to ionizing radiation, and certain genetic syndromes. Primary treatment goals of BCC include cure of tumor with maximal preservation of function. Although rarely metastatic, BCC can produce substantial local destruction. Treatment modalities can be divided into surgical and nonsurgical therapies, although surgical therapy is the mainstay of treatment. Superficial therapies, such as topical imiquimod or 5-fluorouracil, photodynamic therapy, or cryotherapy, may be effective for anatomically challenging locations where surgery or radiation is contraindicated, but the cure rates of these approaches are lower compared with surgery. Recent FDA-approved hedgehog pathway inhibitors include vismodegib and sonidegib for patients who have exhausted surgical and radiation options for treating advanced BCC. This review contains 4 figures, 5 tables, and 25 references. Key words: cryosurgery, cutaneous basal cell carcinoma, hedgehog pathway inhibitors, Mohs micrographic surgery, pathologic risk factors, photodynamic therapy, radiation therapy, surgical margins, topical therapies 

scholarly journals Vismodegib: The Proof of Concept in Basal Cell Carcinoma

2014 ◽  
Vol 8 ◽  
pp. CMO.S14569 ◽  
Author(s):  
Narjiss Berrada ◽  
Siham Lkhoyali ◽  
Hind Mrabti ◽  
Hassan Errihani
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Signaling Pathway ◽  
Basal Cell ◽  
Hedgehog Signaling ◽  
Treatment Options ◽  
Locally Advanced ◽  
Scientific Data ◽  
Hedgehog Signaling Pathway ◽  
Proof Of Concept

Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases. Management of these patients was complicated due to the lack of scientific data, the deterioration of a patient's general status, the patient's advanced age, and the presence of multiple comorbidities. The hedgehog signaling pathway is dysregulated in BCC. The exploration of this signaling pathway yielded to a major milestone in the treatment of advanced BCC. Vismodegib (GDC-0449), an oral small-molecule agent that targets the Hedgehog signaling pathway, demonstrates high levels of activity in clinical trials. It was approved in January 2012 for the treatment of locally advanced or metastatic BCC. Vismodegib confirms, once again, the interest in exploring the signal transduction pathways in cancers.

Sign in / Sign up

Export Citation Format

Share Document